HSDT - NASDAQ

Solana Company

HSDT·NASDAQ

$1.48

-15%

HealthcareMedical - Devices

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$86.41M

EPS-1.8500

P/E Ratio-0.80

Earnings Date08/13/2026

303.93M

Assets

8481%

3Y+1658.0%

5Y+4542.0%

10Y+7422.0%

3.02M

Total Liabilities

21%

3Y-67.0%

5Y+13.0%

10Y-26.0%

300.91M

Total Equity

28315%

3Y+3592.0%

5Y+7674.0%

10Y-1858505.0%

Solana Company Funding & Solvency Profile

HSDT · NASDAQ

Current Assets

Cash & Cash Equivalents7.28M

Net Receivables0.00

Inventory1.12M

Other Current Assets22.75M

Total Current Assets31 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments5.62M

Other Non-Current Assets267.16M

Total Non-Current Assets273 M

Total Assets

303.93M

Financial Health Analysis

Current Ratio

10.33x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.01x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

28 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

10% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Solana Company Balance Sheet

HSDT • NASDAQ

Solana Company Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Mar 2016	Mar 2015	Mar 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	7.3M	1.1M	5.2M	14.5M	11M	3.3M	5.5M	25.6M	5.6M	2.6M	418.9K	16K
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	378K	0.0
Cash & Short-Term Investments	7.3M	1.1M	5.2M	14.5M	11M	3.3M	5.5M	25.6M	5.6M	2.6M	796.9K	16K
Net Receivables	0.0	635K	637K	343K	251K	230K	574K	275K	704K	399.1K	8.8K	0.0
Accounts Receivables	0.0	70K	117K	71K	66K	74K	210K	275K	0.0	0.0	0.0	0.0
Other Receivables	0.0	565K	520K	272K	185K	156K	364K	0.0	704K	399.1K	8.8K	0.0
Inventory	1.1M	1.1M	457K	589K	476K	389K	598K	392K	0.0	0.0	0.0	0.0
Prepaids	0.0	603K	689K	817K	862K	735K	610K	447K	0.0	502.3K	410.6K	300K
Other Current Assets	22.8M	7K	333K	399K	0.0	0.0	0.0	264K	352K	495.4K	0.0	0.0
Total Current Assets	31.2M	3.4M	7.3M	16.7M	12.6M	4.7M	7.2M	27M	6.6M	4M	1.2M	316K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	118K	230K	450K	412K	576K	1.3M	554K	173K	0.0	0.0	0.0
Goodwill	0.0	0.0	0.0	0.0	763K	759K	1.2M	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	24K	140K	333K	527K	582K	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	24K	140K	1.1M	1.3M	1.8M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	5.6M	0.0	0.0	0.0	0.0	0.0	0.0	294K	0.0	0.0	0.0	0.0
Other Non-Current Assets	267.2M	0.0	140K	0.0	0.0	0.0	18K	18K	18K	0.0	0.0	0.0
Total Non-Current Assets	272.8M	118K	394K	590K	1.5M	1.9M	3.1M	866K	191K	0.0	0.0	0.0
Total Assets	303.9M	3.5M	7.7M	17.3M	14.1M	6.5M	10.3M	27.8M	6.8M	4M	1.2M	316K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.9M	1.2M	531K	627K	1.1M	747K	1.7M	2.4M	3.5M	0.0	0.0	215.9K
Accounts Payable	1.9M	873K	531K	627K	1.1M	747K	1.7M	2.4M	3.5M	0.0	0.0	215.9K
Other Payables	0.0	356K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	24K	509K	509K	712K	496K	722K	876K	442K	0.0	0.0	0.0
Short Term Debt	0.0	0.0	45K	54K	3K	59K	172K	0.0	0.0	0.0	0.0	368K
Capital Lease Obligations (Current)	0.0	12K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	39K	43K	27K	148K	281K	430K	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	1.1M	859K	751K	771K	721K	841K	802K	14.7M	10.4M	2.3M	1.2M	0.0
Total Current Liabilities	3M	2.2M	1.9M	2M	2.7M	2.4M	3.8M	18M	14.3M	2.3M	1.2M	583.9K
NON-CURRENT LIABILITIES
Deferred Revenue (Non-Current)	0.0	79K	128K	175K	193K	220K	245K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	241K	3.3M	6.9M	0.0	0.0	0.0	0.0	0.0	1.7M	1.6M	0.0
Total Non-Current Liabilities	0.0	320K	3.5M	7.1M	193K	252K	710K	0.0	0.0	1.7M	1.6M	0.0
Capital Lease Obligations	0.0	12K	12K	56K	0.0	32K	465K	0.0	0.0	0.0	0.0	0.0
Total Liabilities	3M	2.5M	5.3M	9.1M	2.8M	2.7M	4.5M	18M	14.3M	4.1M	2.8M	583.9K
SHAREHOLDERS' EQUITY
Common Stock	44K	4K	1K	28K	4K	1K	31K	26K	52.2M	24.3M	16.4M	200.0
Additional Paid-In Capital	513.7M	172.4M	163M	159.6M	149.4M	123.9M	111.5M	105.4M	6.6M	2.9M	2.4M	9.3M
Retained Earnings	-212.6M	-171.7M	-160M	-151.1M	-137M	-118.9M	-104.8M	-95M	-66.4M	-26.3M	-19.4M	-9.6M
Accumulated Other Comprehensive Income/Loss	-261K	333K	-673K	-388K	-1.1M	-1.1M	-902K	-591K	47K	-999.4K	-932.1K	0.0
Total Stockholders' Equity	300.9M	1.1M	2.4M	8.2M	11.3M	3.9M	5.8M	9.9M	-7.5M	-16.2K	-1.6M	-268K
Total Equity	300.9M	1.1M	2.4M	8.2M	11.3M	3.9M	5.8M	9.9M	-7.5M	-16.2K	-1.6M	-268K
SUMMARY
Total Liabilities & Equity	303.9M	3.5M	7.7M	17.3M	14.1M	6.5M	10.3M	27.8M	6.8M	4M	1.2M	316K
Total Investments	5.6M	0.0	0.0	0.0	0.0	0.0	0.0	294K	0.0	0.0	378K	0.0
Total Debt	0.0	12K	57K	110K	3K	91K	637K	0.0	0.0	0.0	0.0	368K
Net Debt	-7.3M	-1.1M	-5.1M	-14.4M	-11M	-3.2M	-4.8M	-25.6M	-5.6M	-2.6M	-418.9K	352.1K
Shares Outstanding	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997	40,299,997

SEC Filings

HSDT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 15, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 27, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 08, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 30, 2026	2026	View Filing

Showing 1 to 10 of 292 filings

Related Guides

Blog Categories

Continue your HSDT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.